Solanezumab scFv-Transferrin Fusion for Barrier-Penetrating Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Many antibodies face challenges in crossing biological barriers such as the blood-brain barrier and blood-eye barrier, and entering cancerous cells due to their size and lack of specific targeting mechanisms, limiting their efficacy and application in certain diseases.
Innovation Solution
A single-chain variable fragment (scFv) is designed to bind with the N-methyl lobe of the transferrin protein, utilizing transferrin receptor-mediated endocytosis to enhance cellular uptake, and incorporating cleavable linkers that respond to specific cellular environments for targeted and controlled release of therapeutic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If whole antibodies are used for therapeutic treatment, then effector functions and half-life are improved, but penetration across biological barriers and cellular uptake are reduced
Solution Approach 1:
The antibody is segmented into its functional components: the scFv retains antigen-binding capability while the Fc region is removed. This segmentation allows the scFv to penetrate biological barriers more effectively while the transferrin conjugation provides the necessary half-life extension through receptor-mediated recycling.
Solution Approach 2:
Transferrin acts as an intermediary molecule that mediates both cellular uptake through transferrin receptor binding and half-life extension through receptor-mediated endocytosis and recycling. This intermediary solves the contradiction by providing both penetration and duration functions that the scFv alone cannot achieve.
2Speed
If scFv is used for therapeutic treatment, then penetration across biological barriers and cellular uptake are improved, but effector functions and half-life are reduced
Solution Approach 1:
The scFv is merged with transferrin to create a fusion protein that combines the penetrating capabilities of scFv with the half-life extending properties of transferrin. The transferrin portion enables receptor-mediated endocytosis and cellular recycling, thereby extending circulation time while the scFv maintains its antigen-binding and penetration functions.
3Reliability
If antibodies are used for targeting specific tissues, then therapeutic efficacy is improved, but off-target effects and delivery challenges persist
Solution Approach 1:
The transferrin-conjugated scFv exhibits local quality by utilizing the differential expression of transferrin receptors across tissue types. Tissues with high TfR expression (such as tumor cells, brain endothelial cells, and retinal cells) selectively uptake the conjugate, providing targeted delivery while minimizing off-target effects in tissues with lower receptor expression.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The scFv-conjugate achieves enhanced delivery across biological barriers, reduces off-target effects, and increases therapeutic efficacy by ensuring prolonged interaction with target cells, thereby improving treatment outcomes for various diseases.
Implementation Method 1
A single-chain variable fragment (scFv) is designed to bind with the N-methyl lobe of the transferrin protein, utilizing transferrin receptor-mediated endocytosis to enhance cellular uptake
Implementation Method 2
incorporating cleavable linkers that respond to specific cellular environments for targeted and controlled release of therapeutic agents
Data Source
AI summary
The efficacy and indication of solanezumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.